Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings

Background: The follicle-stimulating hormone (FSH)-receptor (FSHR) has been reported to be an attractive target for antibody therapy in human cancer. However, divergent immunohistochemical (IHC) findings have been reported for FSHR expression in tumor tissues, which could be due to the specificity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Möker, Nina, Peters, Solveig, Rauchenberger, Robert, Ghinea, Nicolae, Kunz, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698838/
https://www.ncbi.nlm.nih.gov/pubmed/31548530
http://dx.doi.org/10.3390/antib6040015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698838/
https://www.ncbi.nlm.nih.gov/pubmed/31548530
http://dx.doi.org/10.3390/antib6040015

Ejemplares similares